Insider Transactions in Q1 2022 at 89bio, Inc. (ETNB)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2022
|
Michael R Hayden |
BUY
Open market or private purchase
|
Indirect |
6,250
+6.93%
|
$18,750
$3.62 P/Share
|
|
Feb 17
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,200
+35.14%
|
-
|
|
Feb 17
2022
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+26.11%
|
-
|
|
Feb 17
2022
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+26.11%
|
-
|
|
Feb 17
2022
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.06%
|
-
|
|
Feb 17
2022
|
Ram Waisbourd Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+36.11%
|
-
|
|
Feb 05
2022
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,363
-4.19%
|
$6,815
$5.23 P/Share
|
|
Feb 05
2022
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,088
-4.09%
|
$20,440
$5.23 P/Share
|
|
Feb 05
2022
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,022
-4.35%
|
$5,110
$5.23 P/Share
|
|
Feb 05
2022
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,363
-4.19%
|
$6,815
$5.23 P/Share
|
|
Feb 01
2022
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$35,000
$5.7 P/Share
|
|
Feb 01
2022
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+40.0%
|
$7,000
$1.93 P/Share
|
|
Jan 28
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+5.17%
|
$15,000
$6.14 P/Share
|
|
Jan 27
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+10.34%
|
$35,000
$7.5 P/Share
|
|
Jan 26
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
21,482
-0.58%
|
$171,856
$8.38 P/Share
|
|
Jan 25
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,091
-1.32%
|
$392,728
$8.4 P/Share
|